Filing Flows › Humacyte (HUMA) › Q2 2026 › vs Q1 2026
Humacyte (HUMA) Q2 2026 vs Q1 2026 (quarter over quarter)
Humacyte's revenue fell $89K (-18%) from $495K in Q1 2026 to $406K in Q2 2026.
Humacyte, Q2 2026: revenue $406K (+35% year over year), net loss $36.8M, operating cash flow −$22.1M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $406K | $495K | −$89K | -18% |
| Net loss | $36.8M | $17.6M | $19.2M | +109% |
| Costs & expenses | $37.2M | $29.4M | $7.8M | +26% |
| Operating costs | $27.4M | $29.4M | −$2.0M | -7% |
| Interest & other, net | $9.8M | −$11.3M | $21.1M | — |
| Cost of revenue | $1.2M | $2.0M | −$807K | -40% |
| Research & development | $18.1M | $19.5M | −$1.3M | -7% |
| General & admin | $8.0M | $7.9M | $97K | +1% |
| Operating cash sources | $36.8M | $17.6M | $19.2M | +109% |
| Depreciation | $1.3M | $1.3M | −$5K | -0.4% |
| Share-based compensation | $2.6M | $3.2M | −$562K | -18% |
| Working capital & other | $10.8M | −$12.0M | $22.8M | — |
| Cash used in operations | $22.1M | $25.1M | −$3.0M | -12% |
| Net loss absorbed | $36.8M | $17.6M | $19.2M | +109% |
Questions
How much did Humacyte's revenue grow quarter over quarter in Q2 2026?
Humacyte's revenue fell $89K (-18%) from $495K in Q1 2026 to $406K in Q2 2026.